The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin.
 
Hironobu Hashimoto
No Relationships to Disclose
 
Takako Yanai
No Relationships to Disclose
 
Kengo Nagashima
No Relationships to Disclose
 
Natsuko Okita Tsuda
No Relationships to Disclose
 
Hidehito Horinouchi
No Relationships to Disclose
 
Tomomi Takiguchi
No Relationships to Disclose
 
Fumiyoshi Ohyanagi
No Relationships to Disclose
 
Masahiko Nakao
No Relationships to Disclose
 
Koji Takeda
Honoraria - Lilly
 
Toshiaki Nakayama
No Relationships to Disclose
 
Hiroshi Sakai
No Relationships to Disclose
 
Takahiro Arai
No Relationships to Disclose
 
Koichi Minato
No Relationships to Disclose
 
Yuki Kogure
No Relationships to Disclose
 
Daijiro Harada
No Relationships to Disclose
 
Kenichi Suzuki
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Shimada
No Relationships to Disclose
 
Satoru Iwasa
No Relationships to Disclose
 
Noboru Yamamoto
No Relationships to Disclose